News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

ARACOG: Is there a difference in cognitive effects between darolutamide and enzalutamide?
23 Jun 2026
byNatalia Reoutova
ARACOG, a phase II randomized trial, reports a significantly greater decline in objectively assessed cognitive function for advanced prostate cancer patients treated with enzalutamide vs darolutamide over 24 weeks, according to data presented at ASCO 2026.
23 Jun 2026

Chiauranib extends PFS in platinum-resistant ovarian cancer, including in anti-angio–exposed patients
23 Jun 2026
byNatalia Reoutova
Chiauranib plus weekly paclitaxel significantly extends progression-free survival (PFS) in patients with platinum-resistant or -refractory ovarian cancer, including those previously treated with anti-angiogenic agents, according to the findings of the phase III CHIPRO trial presented at ASCO 2026.
23 Jun 2026






